



Wiley Rein &amp; Fielding LLP

RECEIVED  
CENTRAL FAX CENTER

MAY 19 2004

OFFICIAL

1776 K STREET NW  
WASHINGTON, DC 20006PHONE 202.719.7000  
FAX 202.719.7049

## Facsimile

TO	FAX NUMBER	PHONE NUMBER
U.S. Patent and Trademark Office	703-872-9306	
FROM	Mary K. Drake	PHONE NUMBER 202.719.3258
DATE	May 19, 2004	PAGES TO FOLLOW 5
USER NUMBER	1991	CLIENT NUMBER 80375.0021

MESSAGE: RE: APPL. NO. 10/724,225  
FILED: DECEMBER 1, 2003  
TITLE: "ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE PROTEIN  
MDM2, AND USE THEREOF IN THE TREATMENT OF CANCERS"  
EXAMINER: UNASSIGNED  
ART UNIT: 1614  
CONFIRMATION NO.: 9762

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this Information Disclosure Statement is being facsimile transmitted to the United States Patent and Trademark Office on May 19, 2004.

By:   
Mary K. Drake

Please contact Mary Drake at 202.719.3258 if you do not receive this facsimile in its entirety.

**Confidentiality Note:** The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this facsimile message is strictly prohibited. If you have received this message in error, please immediately notify us by telephone and return the original message to us at the address above via the United States Postal Service. *Thank you.*

MAY 19 2004

OFFICIAL

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No. : 10/724,225 Confirmation No.: 9762  
Applicant : Bruno TOCQUE, et al.  
Filed : December 1, 2003  
TC/A.U. : 1614  
Examiner : Unassigned

Docket No. : ST95050-US/A  
Customer No. : 29693

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

The subject application is a Divisional Application of U.S. Application No. 09/029,327 filed on March 23, 1998. In accordance with 37 C.F.R. § 1.98(d), patent documents and published articles which were cited in the prior application are listed on the accompanying Forms SB/08 and PTO-892, but copies of these documents are not enclosed as they were provided in the prior application.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action and/or within three months of the filing date of the application. It is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-1129.

Appl. No. 10/724,225

Information Disclosure Statement dated May 19, 2004

While the information and references disclosed in this Information Disclosure Statement are submitted pursuant to 37 C.F.R. § 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to is "prior art" to this invention. Applicants reserve the right to contest the "prior art" status of any information submitted or asserted against the application.


In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. This Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed documents and information.

Dated: May 19, 2004

Respectfully submitted,

**WILEY REIN & FIELDING LLP**

By:

  
David J. Kulk  
Reg. No. 38,576

**WILEY REIN & FIELDING LLP**  
Attn: Patent Administration  
1776 K Street, N.W.  
Washington, D.C. 20006  
Telephone: 202.719.7000  
Facsimile: 202.719.7049



APR 17 1998

PTO/SB/08A (8-95)

Approved for use through 09/30/98, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box



1449A/PTO		U.S. Department of Commerce Patent and Trademark Office		Complete if Known	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	09/029,327
				Filing Date	March 3, 1998
				First Named Inventor	Tocque et al.
				Group Art Unit	1635
				Examiner Name	Karen Lacourciere
Sheet	2	of	2	Attorney Docket Number	ST95050 -US

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	T
KAL	PA	Leng et al., Human oncoprotein MDM2 interacts with the TATA-binding protein in vitro and in vivo, International Journal of Oncology 6: 251-259 (1995)	
KAL	PB	Leveillard et al., The Oncoprotein MDM2 Associates With The TATA-Binding Protein (TBP), Journal of Cellular Biochemistry Supp. 19A (1995)	
KAL	PC	Chen et al., Mapping of the p53 and mdm-2 Interaction Domains, Molecular & Cellular Biology, 13(7): 4107-4114 (1993)	

EXAMINER SIGNATURE: <i>Karen Lacourciere</i>	DATE CONSIDERED: 02-23-00
--	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for